CANY
EDIT icon

Caxton Associates (New York)’s Editas Medicine EDIT Stock Holding History

Caxton Associates (New York)’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-114,363
Closed -$390K – 541
2024
Q3 		$390K Sell
114,363
-14,147
-11% -$61.6K 0.01% 401
2024
Q2 		$600K Buy
+128,510
New +$725K 0.02% 321
2024
Q1 		– Sell
-32,553
Closed -$330K – 484
2023
Q4 		$330K Sell
32,553
-28,670
-47% -$252K 0.02% 385
2023
Q3 		$478K Buy
61,223
+27,678
+83% +$237K 0.07% 253
2023
Q2 		$276K Sell
33,545
-74,163
-69% -$646K 0.04% 354
2023
Q1 		$781K Buy
107,708
+93,375
+651% +$830K 0.12% 191
2022
Q4 		$127K Buy
+14,333
New +$157K 0.01% 410
2022
Q3 		– Sell
-17,101
Closed -$202K – 513
2022
Q2 		$202K Buy
+17,101
New +$229K 0.02% 465

Other funds holding EDIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Caxton Associates (New York)'s EDIT Position: Q4 2024 in Review

Caxton Associates (New York) sold out of Editas Medicine (EDIT) in Q4 2024, closing a stake of 114,363 shares — an estimated $390K sold.

Caxton Associates (New York) first reported a position in EDIT in Q2 2022 and held it in 8 quarters. The position peaked at $781K in Q1 2023. 206 funds tracked by Wall St. Rank hold EDIT as of Q4 2024.

  • Caxton Associates (New York) reported no remaining Editas Medicine position as of Q4 2024 after selling out during the quarter.
  • Caxton Associates (New York) sold 114,363 Editas Medicine shares in Q4 2024, an estimated $390K.
  • Caxton Associates (New York) first reported a position in Editas Medicine in Q2 2022 and held it in 8 quarters.
  • Caxton Associates (New York)'s Editas Medicine position peaked at $781K in Q1 2023.
  • 206 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.